All In Biotech

Drug Trial Radar · NCT06923228

A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis

A Single-Blind, Prospective Clinical Study to Assess the Efficacy, Safety and Tolerability of CGB-500 1% Tofacitinib Ointment vs. an Active Comparator for Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

3

Actual

Start

Apr 21, 2025

Primary completion

Jul 30, 2025

Study completion Sep 30, 2025

Sponsor

Lead sponsor
CAGE Bio Inc.Industry
Sponsor type
Industry
First posted
Apr 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if drug CGB-500 works to treat atopic dermatitis in subjects 12 years of age or older. It will also learn about the safety of CGB-500. The main questions it aims to answer are: Does CGB-500 decrease the severity of atopic dermatitis on the skin? What medical problems do participants have when taking drug CGB-500? Researchers will compare CGB-500 to a an approved product (1.5% ruxolitinib) to see if CGB-500 works to treat atopic dermatitis. Participants will: Apply CGB-500 and ruxolitinib to different locations on their body twice a day for four weeks. Visit the clinic six times for checkups and tests Keep a diary of their symptoms and when they apply the product

Conditions

  • Atopic Dermatitis (AD)

Interventions

  • CGB-500 Ointment with 1% tofacitinibDrug

    experimental drug

  • Ruxolitinib 1.5% Cream QDDrug

    topical cream

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. evaluate effectivenessTime frame: From enrollment to end of study at 4 weeks
  2. Safety and tolerabilityTime frame: From enrollment to end of study at 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Center for Dermatology Clinical Research

    Fremont, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.